HealthEquity/$HQY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About HealthEquity
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
- Ticker
- $HQY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,814
- Headquarters
- Draper, United States
- Website
- www.healthequity.com
HealthEquity Metrics
BasicAdvanced
$7.6B
33.30
$2.76
0.23
-
Price and volume
Market cap
$7.6B
Beta
0.23
52-week high
$107.62
52-week low
$72.76
Average daily volume
855K
Financial strength
Current ratio
2.993
Quick ratio
2.459
Long term debt to equity
0.483
Total debt to equity
0.488
Interest coverage (TTM)
6.78%
Profitability
EBITDA (TTM)
513.607
Gross margin (TTM)
71.25%
Net profit margin (TTM)
17.36%
Operating margin (TTM)
26.13%
Effective tax rate (TTM)
23.39%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
6.65%
Return on equity (TTM)
11.43%
Valuation
Price to earnings (TTM)
33.302
Price to revenue (TTM)
5.728
Price to book
3.83
Price to tangible book (TTM)
-10.81
Price to free cash flow (TTM)
17.867
Free cash flow yield (TTM)
5.60%
Free cash flow per share (TTM)
5.151
Growth
Revenue change (TTM)
7.34%
Earnings per share change (TTM)
67.87%
3-year revenue growth (CAGR)
13.24%
10-year revenue growth (CAGR)
24.31%
3-year earnings per share growth (CAGR)
163.56%
10-year earnings per share growth (CAGR)
21.61%
What the Analysts think about HealthEquity
Analyst ratings (Buy, Hold, Sell) for HealthEquity stock.
Analyst projections of the future price of HealthEquity stock.
Bulls say / Bears say
HealthEquity is still adding accounts and assets at a healthy pace: HSAs rose 8% year on year to 10.7 million, HSA assets rose 14% to $37.9 billion, and new HSAs from sales increased 24%. Management raised fiscal 2027 guidance for revenue, adjusted EBITDA and non-GAAP earnings. (GlobeNewswire, MarketWatch)
Operating leverage is improving faster than the top line. Second-quarter adjusted EBITDA rose 11% and the margin reached a record 48%, helped by technology-enabled service efficiencies, while operating cash flow increased year on year and funded substantial share repurchases. (GlobeNewswire, HealthEquity)
HealthEquity has additional growth options beyond organic account additions. Its latest annual report describes direct HSA enrolment for newly eligible Bronze-plan customers and a pipeline of potential HSA portfolio acquisitions, while the latest results say the company retains capacity for acquisitions and further investment. (MarketScreener, GlobeNewswire)
Custodial revenue is a major earnings driver, so lower cash yields could slow profit growth. Management flagged sensitivity to floating-rate balances and said roughly $2.3 billion of HSA cash remains in contracts due to reprice during fiscal 2027, leaving greater rate exposure beyond the current guidance period. (TradingKey, GlobeNewswire)
Competition is putting pressure on HealthEquity’s core service pricing. Management called year-on-year price reductions a headwind to service revenue and said competitors are also cutting costs, so some of the benefit from automation may need to be passed to clients rather than retained as margin. (Longbridge, TIKR)
The model remains exposed to policy and trust-related shocks. HealthEquity’s own risk disclosures highlight dependence on tax-advantaged HSA rules and exposure to fraud and cybersecurity incidents, while recent reporting noted an ongoing cybersecurity-related class action and regulatory inquiries. (GlobeNewswire, MetaTrader)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
HealthEquity Financial Performance
Revenues and expenses
HealthEquity Earnings Performance
Company profitability
Upcoming events
No upcoming events
HealthEquity News
AllArticlesVideos
Funds containing HealthEquity
AllEURGBPUSD
Fund name | Fund size | $HQY weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.25% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.25% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.23% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.23% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.